BLU:TSX-BELLUS Health Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 11.01

Change

+0.37 (+3.48)%

Market Cap

CAD 1.14B

Volume

0.13M

Avg Analyst Target

CAD 15.00 (+36.24%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BELLUS Health Inc (BLU) Stock Analysis:
Based on the BELLUS Health Inc stock forecasts from 2 analysts, the average analyst target price for BELLUS Health Inc is CAD 15.00 over the next 12 months. BELLUS Health Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BELLUS Health Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, BELLUS Health Inc’s stock price was CAD 11.01. BELLUS Health Inc’s stock price has changed by +31.07% over the past week, +5.46% over the past month and +150.23% over the last year.

About

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Ph ...Read More

Company Website : https://www.bellushealth.com

Address : 275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7

Employees : 40

Fiscal Year End : December

Currency: CAD

Country : Canada

Technical Indicators

Beta : -0.49

52 Week High : 12.59

Short Ratio : 5.33

52 Week Low : 3.32

Shorted Shares : 528,334

200 Day Moving Average : 7.87

Shorted Shares Previous Month : 302,329

50 Day Moving Average : 9.31

Shares Held By Insiders : 11.57%

Short Percentage : 2.09%

Shares Held by Institutions : 84.87%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
TRIL:CA Trillium Therapeutics Inc

N/A

 CAD2.43B 1.80 N/A
LMNL:CA Liminal BioSciences Inc

N/A

 CAD0.54B 1.28 N/A
FRX:CA Fennec Pharmaceuticals Inc

-0.16 (-2.30%)

 CAD0.18B 30.20 N/A
APS:CA Aptose Biosciences Inc

+0.06 (+4.55%)

 CAD0.13B N/A N/A
IMV:CA IMV Inc

-0.04 (-3.13%)

 CAD0.11B -99,999.99 N/A
BCT:CA BriaCell Therapeutics Corp.

-0.60 (-9.45%)

 CAD0.10B N/A N/A
ONC:CA Oncolytics Biotech Inc

+0.01 (+0.68%)

 CAD0.08B N/A N/A
MDNA:CA Medicenna Therapeutics Corp

-0.07 (-4.90%)

 CAD0.08B 5.40 N/A
RVX:CA Resverlogix Corp

-0.01 (-1.59%)

 CAD0.08B 27.50 26.37
MBX:CA Microbix Biosystems Inc

-0.02 (-4.26%)

 CAD0.06B 15.67 8.90

ETFs Containing BLU:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.26% 94% A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.26% 94% A 90% A-
Trailing 12 Months  
Capital Gain 150.23% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 150.23% 100% A+ 98% A+
Trailing 5 Years  
Capital Gain 1,144.07% 93% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,144.07% 93% A 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 105.74% 94% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.74% 94% A 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 127.67% 18% F 5% F
Risk Adjusted Return 82.82% 100% A+ 89% B+
Market Capitalization 1.14B 100% A+ 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.87 53% F 22% F
Price / Cash Flow Ratio -18.55 100% A+ 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -32.44% 80% B- 12% F
Return on Invested Capital -33.29% 71% C- 8% F
Return on Assets -19.80% 88% B+ 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.33 53% F 24% F
Short Percent 2.09% 6% F 50% F
Beta -0.49 100% A+ 100% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector